Moesin Expression in Clear Cell Renal Cell Carcinoma

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All cases of ccRCC.
Tissue blocks with material adequate for immunohistochemical evaluation.
All cases with accessible clinical data.

Exclusion criteria

Cases of renal neoplasms other than ccRCC.
Patients who received preoperative chemotherapy or radiotherapy.
Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
Cases with insufficient/destructed material.
Patients with inadequate clinical data.

Treatment and study plan

Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma

Genetic

Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.

Primary outcomes

Detection of Moesin in renal cell carcinoma

Time frame: 6 months

different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.

Important dates

Study start: 2017
Primary completion: 2021
Study completion: 2021
First posted: Sep 28, 2023
Registry last updated: Sep 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed